Results 1 to 10 of about 19,208 (277)
Assessment of Micafungin Dosage Regimens in Patients with Cancer Using Pharmacokinetic/Pharmacodynamic Modeling and Monte Carlo Simulation [PDF]
Antibiotics, 2021 Micafungin is widely used for invasive candidiasis, especially in critically ill patients and those with cancer, and for empirical antifungal therapy in patients with neutropenic fever.
Saeed Alqahtani +5 more
doaj +3 more sources
Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy [PDF]
BMC Cancer, 2019 Background Micafungin is a well-tolerated and effective prophylactic antifungal agent used in hematologic diseases. In this prospective trial, we evaluated the efficacy and safety of prophylactic micafungin during first induction chemotherapy in patients
Hyunkyung Park +10 more
doaj +3 more sources
Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA Replication
Viruses, 2023 Echinocandin antifungal drugs, including micafungin, anidulafungin, and caspofungin, have been recently reported to exhibit antiviral effects against various viruses such as flavivirus, alphavirus, and coronavirus. In this study, we focused on micafungin
Shogo Nakajima +6 more
doaj +2 more sources
Pharmaceuticals, 2021 Dengue fever is an arbovirus disease caused by infection with the dengue virus (DENV). Half of the world’s population lives under the threat of dengue fever, however, researchers have yet to develop any drugs that are clinically applicable to this ...
Yen-Chen Chen +5 more
doaj +2 more sources
Pharmaceuticals, 2023 Background: Neonates may require higher doses of micafungin than adults to reach the therapeutic effect for increased plasma clearance. Only poor and inconclusive data are available still now to support this hypothesis, especially with regard to central ...
Domenico Umberto De Rose +9 more
doaj +2 more sources
Tropical Medicine and Infectious Disease, 2022 Micafungin is the empiric antifungal agent of choice for the treatment of invasive candidiasis (IC). Pathophysiologic changes that occur in obese and/or critically ill patients can alter micafungin serum concentrations and the probability of target ...
Victoria C. Grant +5 more
doaj +2 more sources
BMC Infectious Diseases, 2023 Background Saccharomyces cerevisiae is ubiquitous in the gastrointestinal tract and known as brewer's or baker's yeast. We experienced a case of S. cerevisiae and Candida glabrata co-infectious bloodstream infection.
Kento Furuya +6 more
doaj +2 more sources
Journal of Fungi, 2021 Introduction: Micafungin is a recommended echinocandin antifungal agent for candidemia treatment and prophylaxis. However, overuse of echinocandin antifungals may cause resistance.
Yasutaka Sakamoto +11 more
doaj +2 more sources
Antimicrobial Agents and Chemotherapy, 2022 Candida bloodstream infections are associated with high attributable mortality, where early initiation of adequate antifungal therapy is important to increase survival in critically ill patients. The exposure variability of micafungin, a first-line agent
J. Boonstra +5 more
semanticscholar +3 more sources
Does DHN-Melanin Always Protect Fungi against Antifungal Drugs? The Fonsecaea/Micafungin Paradigm
Microbiology Research, 2022 Several human pathogenic fungi produce melanin. One of its properties during parasitism is the protection against antifungal drugs. This occurs with the agents of chromoblastomycosis, in which DHN-melanin reduces antifungal susceptibility to terbinafine ...
Rowena Alves Coelho +7 more
doaj +2 more sources